PapersFlow Research Brief
Genetic and rare skin diseases.
Research Guide
What is Genetic and rare skin diseases.?
Genetic and rare skin diseases are a cluster of disorders caused by genomic rearrangements and mutations in genes such as NEMO and ATP2C1, leading to conditions like incontinentia pigmenti, Hailey-Hailey disease, epidermal nevus syndromes, and Darier disease through disrupted NF-κB activation and calcium pump function.
This field encompasses 35,306 papers on the molecular basis of genomic rearrangement disorders in skin diseases. Mutations in NEMO affect NF-κB activation, contributing to incontinentia pigmenti and related syndromes. Conditions like Hailey-Hailey disease and Darier disease arise from ATP2C1 mutations impairing calcium pump function, with growth data over 5 years not available.
Topic Hierarchy
Research Sub-Topics
Incontinentia Pigmenti
This sub-topic examines NEMO gene mutations causing X-linked dominant skin lesions and neurological complications in females. Researchers investigate molecular pathogenesis, genotype-phenotype correlations, and targeted therapies.
Hailey-Hailey Disease
Studies focus on ATP2C1 mutations disrupting calcium pumps leading to acantholysis and chronic vesicles. Research covers pathogenesis, acantholytic mechanisms, and novel treatments like botulinum toxin.
Darier Disease
This area investigates ATP2A2 mutations causing dyskeratosis and warty dyskeratomas via SERCA2 dysfunction. Researchers study desmosomal defects, Hailey-Hailey overlaps, and retinoid therapies.
Epidermal Nevus Syndromes
Research analyzes mosaic RASopathies and PI3K pathway mutations in ILVEN, nevus sebaceus, and Schimmelpenning syndrome. It explores segmental manifestations, postzygotic genetics, and surgical interventions.
NF-κB Signaling in Skin Development
This sub-topic covers NEMO and IKK deficiencies causing anhidrotic ectodermal dysplasia and skin inflammation. Studies elucidate NF-κB activation in epidermal appendage formation and innate immunity.
Why It Matters
These diseases impact clinical management through identification of therapeutic targets in Hedgehog signaling, relevant to basal cell nevus syndrome and epidermal nevus syndromes. Von Hoff et al. (2009) demonstrated that GDC-0449, a Hedgehog pathway inhibitor, showed antitumor activity in 33 patients with locally advanced or metastatic basal-cell carcinoma, with 18 achieving objective responses in a phase I trial (NCT00607724). Rudin et al. (2009) reported complete response in a 26-year-old man with metastatic medulloblastoma refractory to prior therapies after treatment with GDC-0449. Gorlin and Goltz (1960) defined the nevoid basal-cell epithelioma syndrome with jaw cysts and bifid ribs, establishing diagnostic criteria still used for genetic counseling in affected families.
Reading Guide
Where to Start
"Altered Neural Cell Fates and Medulloblastoma in Mouse patched Mutants" by Goodrich et al. (1997), as it provides foundational evidence linking PTCH mutations to skin tumor syndromes through accessible mouse model phenotypes.
Key Papers Explained
Goodrich et al. (1997) "Altered Neural Cell Fates and Medulloblastoma in Mouse patched Mutants" establishes PTCH as a tumor suppressor in skin-related syndromes. Stone et al. (1996) "The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog" identifies its receptor function, while Xie et al. (1998) "Activating Smoothened mutations in sporadic basal-cell carcinoma" reveals downstream activators. Chen et al. (2002) "Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened" and Taipale et al. (2000) "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine" build therapeutic strategies reversing these effects.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Clinical translation dominates with Von Hoff et al. (2009) "Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma" and Rudin et al. (2009) "Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449" showing GDC-0449 efficacy in human trials for basal-cell carcinoma and related tumors.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Altered Neural Cell Fates and Medulloblastoma in Mouse <i>patc... | 1997 | Science | 1.7K | ✕ |
| 2 | Inhibition of Hedgehog signaling by direct binding of cyclopam... | 2002 | Genes & Development | 1.5K | ✓ |
| 3 | Activating Smoothened mutations in sporadic basal-cell carcinoma | 1998 | Nature | 1.3K | ✕ |
| 4 | Effects of oncogenic mutations in Smoothened and Patched can b... | 2000 | Nature | 1.3K | ✕ |
| 5 | The tumour-suppressor gene patched encodes a candidate recepto... | 1996 | Nature | 1.1K | ✕ |
| 6 | Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carc... | 2009 | New England Journal of... | 1.1K | ✓ |
| 7 | Multiple Nevoid Basal-Cell Epithelioma, Jaw Cysts and Bifid Rib | 1960 | New England Journal of... | 1.0K | ✕ |
| 8 | Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor G... | 2009 | New England Journal of... | 1.0K | ✓ |
| 9 | Small molecule modulation of Smoothened activity | 2002 | Proceedings of the Nat... | 980 | ✓ |
| 10 | Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid... | 2018 | — | 923 | ✕ |
Frequently Asked Questions
What role does the PTCH gene play in genetic skin diseases?
The PATCHED (PTC) gene encodes a Sonic hedgehog receptor and tumor suppressor defective in basal cell nevus syndrome. Goodrich et al. (1997) showed that mouse ptc mutants exhibit altered neural cell fates and medulloblastoma, linking PTC inactivation to skin tumor predisposition. Homozygous ptc mutation leads to embryonic lethality with open neural tube and limb defects.
How do Smoothened mutations contribute to basal-cell carcinoma?
Activating Smoothened mutations drive sporadic basal-cell carcinoma by constitutively activating Hedgehog signaling. Xie et al. (1998) identified such mutations in tumor DNA from patients. These findings connect Smoothened to the molecular basis of epidermal nevus syndromes and related skin disorders.
What is the effect of cyclopamine on Hedgehog signaling in skin diseases?
Cyclopamine inhibits Hedgehog signaling by direct binding to Smoothened, blocking pathway activation. Chen et al. (2002) used photoaffinity derivatives to confirm this mechanism, relevant to treating basal cell nevus syndrome. Taipale et al. (2000) showed cyclopamine reverses oncogenic effects of Smoothened and Patched mutations.
What are clinical applications of Hedgehog inhibitors for rare skin cancers?
GDC-0449 targets the Hedgehog pathway in advanced basal-cell carcinoma. Von Hoff et al. (2009) reported antitumor activity in metastatic cases. Rudin et al. (2009) documented its use in medulloblastoma linked to pathway dysregulation, extending to skin manifestations.
What defines nevoid basal-cell epithelioma syndrome?
Nevoid basal-cell epithelioma syndrome involves multiple basal-cell nevi, jaw cysts, and bifid ribs. Gorlin and Goltz (1960) described the condition in a patient with skin lesions from childhood and associated skeletal anomalies. It relates to Patched gene defects in basal cell nevus syndrome.
How was Patched identified as a Sonic hedgehog receptor?
The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Stone et al. (1996) established this role through functional studies. This discovery underpins molecular understanding of skin tumor suppressors in genomic rearrangement disorders.
Open Research Questions
- ? How do NEMO mutations specifically disrupt NF-κB activation in incontinentia pigmenti?
- ? What are the segmental manifestation patterns in epidermal nevus syndromes driven by ATP2C1 alterations?
- ? Can calcium pump disorders in Hailey-Hailey and Darier diseases be targeted beyond symptomatic treatments?
- ? How do Hedgehog pathway interactions with NF-κB influence rare skin disease progression?
- ? What genomic rearrangement mechanisms predominate in calcium pump-related skin disorders?
Recent Trends
The field maintains 35,306 works with no specified 5-year growth rate; high-citation papers from 1996-2009, such as Von Hoff et al. with 1106 citations on GDC-0449 for basal-cell carcinoma, indicate sustained focus on Hedgehog inhibitors for genomic rearrangement skin disorders.
2009No recent preprints or news coverage available.
Research Genetic and rare skin diseases. with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Genetic and rare skin diseases. with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers